Status | Study |
Recruiting |
Study Name: Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry Condition: Atypical Hemolytic-Uremic Syndrome Date: 2012-01-18 |
Completed |
Study Name: An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Condition: Atypical Hemolytic-Uremic Syndrome Date: 2010-08-31 Interventions: Drug: Eculizumab All patients received open-label eculizumab administered intravenously on the following |
Completed |
Study Name: An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Condition: Atypical Hemolytic-Uremic Syndrome Date: 2010-08-31 Interventions: Drug: Eculizumab Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient |
Completed |
Study Name: Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease Condition: Atypical Hemolytic Uraemic Syndrome. Date: 2009-06-29 |
Completed |
Study Name: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Condition: Atypical Hemolytic Uremic Syndrome Date: 2009-02-13 Interventions: Drug: Eculizumab All patients received open-label eculizumab administered intravenously on the following |
Completed |
Study Name: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Condition: Atypical Hemolytic Uremic Syndrome Date: 2009-02-13 Interventions: Drug: Eculizumab All patients received open-label eculizumab administered intravenously on the following |
Completed |
Study Name: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Condition: Atypical Hemolytic Uremic Syndrome Date: 2009-02-12 Interventions: Drug: eculizumab All patients received open-label eculizumab administered intravenously on the following |
Completed |
Study Name: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) Condition: Atypical Hemolytic Uremic Syndrome Date: 2009-02-03 Interventions: Drug: eculizumab All patients received open-label eculizumab administered intravenously on the following |